BioDue
On 18 May 2015 BioDue S.p.A. obtained the admission of the shares to the AIM Italia market organized and managed by Borsa Italiana. The start of negotiations took place on 20 May 2015.
Integræ SIM acted as the Global Coordinator of the private placement and is currently a Specialist of the Issuer. The total amount of the collection in the IPO was approximately Euro 4 million entirely in a capital increase.
The placement price is equal to € 3.55. On the first negotiating day, the security recorded a closing price of Euro 4.82 with a +35.77% increase compared to the Placement Price.
The enterprise. BioDue develops, manufactures, and markets medical devices, dermo-cosmetic products, and food supplements (solids and liquids) with a particular focus on phytotherapeutic preparations. The company operates both on behalf of large national and international pharmaceutical companies (“Industrial Division”) and for its brands (“Pharcos, Selerbe, and Biofta Divisions” dermatological, phytotherapeutic, and ophthalmic products).
Ultima Ricerca BioDue
UPDATE| On June 15, 2026, Doxee announced the approval of its 2026–2028 Business Plan, marking the beginning of a new phase of consolidation and organic growth following the turnaround and integration process achieved through the O³ Strategy. The Plan aims to strengthen the Company’s positioning as a European cloud-sovereign technology vendor for regulated large enterprises, leveraging the scalability of the Doxee Platform® and the evolution of its offering towards integrated, personalized, and compliant solutions. The proprietary platform remains at the core of the strategy, supporting the management of the entire digital communication lifecycle and customers’ mission-critical processes. In this context, artificial intelligence acts as a technological accelerator, enabling controlled and agent-native forms of automation. The Plan also envisages an extension of the core business into adjacent areas, a continued focus on regulated industries, and geographic expansion concentrated on Italy, the DACH region, and France. Following the approval of the 2026–2028 Business Plan, we have revised our estimates for both the current year and the medium term. Specifically, we forecast FY26E Value of Production of € 36.50 million and EBITDA of € 7.00 million, corresponding to an EBITDA margin of 19.2%. Looking ahead, we expect Value of Production to increase to € 49.00 million by FY28E (FY25A–FY28E CAGR of 13.0%), with EBITDA reaching € 13.60 million (corresponding to a 27.8% EBITDA margin), compared to € 6.27 million in FY25A (18.5% EBITDA margin). From a balance sheet perspective, we estimate a net debt position of € 4.04 million by FY28E. We evaluated Doxee’s equity value using both the DCF method and peer group multiples. The DCF method (including a 2.50% company-specific risk in the WACC as a conservative measure) results in an equity value of € 77.2 million. The equity value based on market multiples is € 80.4 million. The average equity value stands at approximately € 78.8 million. The target price is € 6.80, with a BUY rating and MEDIUM risk profile. |
